Crucell: Bavarian Nordic Receives Contract from Janssen
Part of advanced development of prime-boost Ebola vaccine regimen
Read full article »
CEO
Crucell is engaged in the research, development, and production of vaccines that prevent and/or treat various infectious diseases.
Read more